Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1

被引：0

作者：

Locke, Frederick ^{[1
]}

Bartlett, Nancy ^{[2
,3
]}

Jacobson, Caron ^{[4
]}

Oluwole, Olalekan ^{[5
]}

Munoz, Javier ^{[6
]}

Lekakis, Lazaros ^{[7
]}

Topp, Max ^{[8
]}

Avivi, Irit ^{[9
]}

Kim, Jenny ^{[10
]}

Chu, Rong ^{[10
]}

Zheng, Lianqing ^{[10
]}

Rossi, John ^{[10
]}

Bot, Adrian ^{[10
]}

Neelapu, Sattva ^{[11
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO 14263 USA

[3] Washington Univ, Siteman Canc Ctr, St Louis, MO 14263 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[7] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[8] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[9] Sourasky Med Ctr, Tel Aviv, Israel

[10] Kite, Santa Monica, CA USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2020年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-25

引用

页码：S21 / S22

页数：2

共 50 条

[11] DURABILITY OF ANSWERS IN THE ZUMA-1, PIVOTAL STUDY PHASE 2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
Locke, F. L.
Ghobadi, A.
Jacobson, C. A.
Jacobsen, E.
Miklos, D. B.
Lekakis, L. J.
Braunschweig, I
Oluwole, O. O.
Lin, Y.
Siddiqi, T.
Deol, A.
Reagan, P. M.
Farooq, U.
Bot, A.
Jiang, Y.
Rossi, J. M.
Xue, A.
Go, W. Y.
Neelapu, Sattva S.
HAEMATOLOGICA, 2018, 103 : 95 - 96
[12] Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
Neelapu, Sattva S.
Jacobson, Caron A.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Spooner, Clare
Kim, Jenny J.
Miao, Harry
Xue, Allen Xiaodong
Zheng, Yan
Locke, Frederick L.
BLOOD, 2023, 142
[13] Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1
Rossi, John M.
Galon, Jerome
Chang, Edmund
Perbost, Regis
Scholler, Nathalie
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Milletti, Francesca
Go, William Y.
Bot, Adrian
CANCER RESEARCH, 2019, 79 (13)
[14] Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison R.
Neelapu, Sattva S.
Maloney, David G.
Salles, Gilles
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
BLOOD, 2020, 136
[15] Long-term (5 year) overall survival in zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large b-cell lymphoma (LBCL)
Jacobson, C. A.
Locke, F. L.
Ghobadi, A.
Miklos, D. B.
Lekakis, L. J.
Oluwole, O. O.
Lin, Y.
Hill, B. T.
Timmerman, J. M.
Deol, A.
Reagan, P. M.
Stiff, P.
Flinn, I. W.
Farooq, U.
Goy, A. H.
Munoz, J.
Siddiqi, T.
Shen, R. R.
Bot, A. A.
Dong, J.
Singh, K.
Spooner, C.
Karalliyadda, R.
Kim, J. J.
Zheng, Y.
Neelapu, S. S.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 131 - 132
[16] Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David Bernard
Jacobson, Caron A.
Jacobsen, Eric D.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Reagan, Patrick Michael
Farooq, Umar
Deol, Abhinav
Bot, Adrian
Rossi, John M.
Jiang, Yizhou
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[17] Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)
Rossi, John M.
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Go, William Y.
Bot, Adrian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S281 - S281
[18] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Topp, Max
Van Meerten, Tom
Houot, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duhrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose'
BLOOD, 2019, 134
[19] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David Bernard
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[20] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →